Palexia (tapentadol) SPC Update

Author: Shannen Stevens
Category: Medication News, Medication Updates
Date: February 8, 2019

The SPC for tapentadol has been revised to include the additional warning that concomitant use of other sedating medicinal products may result in sedation, respiratory depression, coma and death. Prescribers are advised to consider reducing the dose of one or both agents, if tapentadol is required in addition to one of these classes of drug, and to ensure the treatment is as short as possible. Patients should be followed closely for signs and symptoms of respiratory depression and their caregivers should be made aware of what to look out for.

 

Related Posts